Clinical Trials at Baptist Health Lexington
As of August 2026, 36 paid clinical trials are recruiting at Baptist Health Lexington, located at 4071 TATES CREEK CENTRE DR, SUITE 202, LEXINGTON, KY 40517-3062, phone (859) 260-4390 in Lexington, Kentucky. Active studies at this site cover conditions such as Heart Failure, Obesity and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
36 clinical trials at Baptist Health Lexington
·Clear filters·OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Assessment of CCM in HF With Higher Ejection Fraction
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
SELUTION 4 De Novo Small Vessel IDE Trial
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Common conditions studied in Lexington
- Heart Failure (9 active studies)
- Obesity (9 active studies)
- Acute Myeloid Leukemia (8 active studies)
- Breast Cancer (8 active studies)
- Ovarian Cancer (8 active studies)
- Malignant Solid Neoplasm (7 active studies)
Leading research sponsors in Lexington
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Children's Oncology Group
- NRG Oncology
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Lexington?
There are approximately 452 recruiting clinical trials in Lexington, Kentucky listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lexington pay participants?
Most recruiting trials in Lexington compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lexington?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lexington?
The most common conditions under active study in Lexington include Heart Failure (9), Obesity (9), Acute Myeloid Leukemia (8), Breast Cancer (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lexington?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lexington on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lexington?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lexington?
Recruiting research sites in Lexington include University of Kentucky, University of Kentucky/Markey Cancer Center, Baptist Health Lexington, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lexington right now?
The largest active categories in Lexington are Cancer & tumors (178), Neurology & pain (33), Cardiovascular (30). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Baptist Health Lexington?
Baptist Health Lexington is located at 4071 TATES CREEK CENTRE DR, SUITE 202, LEXINGTON, KY 40517-3062. Use the Google Maps link in the intro above to get directions.
How do I contact Baptist Health Lexington?
You can reach Baptist Health Lexington by phone at (859) 260-4390. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.